电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体

This anti-CTLA-4 (Ipilimumab Biosimilar) antibody is a Humanized 单克隆 antibody detecting CTLA-4 (Ipilimumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
产品编号 ABIN7200671
发货至: 中国

Quick Overview for Recombinant CTLA-4 (Ipilimumab Biosimilar) 抗体 (ABIN7200671)

抗原

CTLA-4 (Ipilimumab Biosimilar)

抗体类型

Recombinant Antibody

适用

宿主

  • 3
  • 1
Humanized

克隆类型

  • 4
单克隆

标记

  • 3
  • 1
This CTLA-4 (Ipilimumab Biosimilar) antibody is un-conjugated

应用范围

  • 3
  • 3
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

质量等级

Research Grade
  • 原理

    Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody

    特异性

    The in vivo grade ipilimumab biosimilar specifically binds to the human CTLA4.

    产品特性

    What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.

    纯化方法

    Protein A or G affinity column

    纯度

    >95 % by reducing SDS-PAGE

    过滤

    0.2 μm filtered

    内毒素水平

    < 1 EU per 1 mg of the protein by the LAL method

    免疫原

    The anti-human CTLA-4 monoclonal antibody ipilimumab biosimilar was produced in the ipilimumab biosimilar CHO stable cell line.

    亚型

    IgG4
  • 应用备注

    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ipilimumab.

    限制

    仅限研究用
  • 状态

    Liquid

    浓度

    > 3 mg/mL

    缓冲液

    PBS, pH 7.4, no stabilizers or preservatives.

    储存液

    Without preservative

    储存条件

    4°C,-20 °C

    储存方法

    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

    有效期

    12 months
  • 抗原

    CTLA-4 (Ipilimumab Biosimilar)

    别名

    Ipilimumab Biosimilar

    物质类

    Biosimilar
You are here:
Chat with us!